Ciardiello, D.; Famiglietti, V.; Napolitano, S.; Esposito, L.; Normanno, N.; Avallone, A.; Latiano, T.; Maiello, E.; Pietrantonio, F.; Cremolini, C.;
et al. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. Cancers 2021, 13, 5715.
https://doi.org/10.3390/cancers13225715
AMA Style
Ciardiello D, Famiglietti V, Napolitano S, Esposito L, Normanno N, Avallone A, Latiano T, Maiello E, Pietrantonio F, Cremolini C,
et al. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. Cancers. 2021; 13(22):5715.
https://doi.org/10.3390/cancers13225715
Chicago/Turabian Style
Ciardiello, Davide, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Nicola Normanno, Antonio Avallone, Tiziana Latiano, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini,
and et al. 2021. "Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy" Cancers 13, no. 22: 5715.
https://doi.org/10.3390/cancers13225715
APA Style
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., & Martini, G.
(2021). Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. Cancers, 13(22), 5715.
https://doi.org/10.3390/cancers13225715
